SCHEMBL5455040

SCHEMBL5455040

NC(=O)c1c(NC(=O)Nc2cccc(Cl)c2Cl)sc2c1CCOC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 2/20 0.55
ANO1 Q5XXA6 3/20 0.55
CNR2 P34972 4/20 0.54
CNR1 P21554 2/20 0.54
KCNH2 Q12809 3/20 0.48
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
PTPRC P08575 1/20 0.45
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPRB P23467 1/20 0.45
PTPRE P23469 1/20 0.45
RAB7A P51149 1/20 0.44
MEN1 O00255 1/20 0.44
EPHB4 P54760 1/20 0.44
KMT2A Q03164 1/20 0.44
FLT3 P36888 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460654 0.92 ANO1 (0.64) CFTRANO1CNR2CNR1KCNH2
SCHEMBL5449480 0.90 CFTR (0.58) CFTRANO1CNR2CNR1KCNH2
SCHEMBL5467763 0.90 CFTR (0.58) CFTRANO1CNR2CNR1KCNH2
SCHEMBL5459052 0.85 CFTR (0.64) CFTRANO1KDM4EALDH1A1LMNA
SCHEMBL5448477 0.84 CFTR (0.58) CFTRANO1CNR2CNR1KCNH2
SCHEMBL5453663 0.84 HPGD (0.54) CFTRANO1CNR2CNR1KCNH2
SCHEMBL5456284 0.84 CFTR (0.58) CFTRANO1CNR2CNR1KCNH2
SCHEMBL5456340 0.84 CFTR (0.60) CFTRANO1CNR2CNR1KCNH2
SCHEMBL5457966 0.83 ANO1 (0.66) CFTRANO1CNR2CNR1NPC1
SCHEMBL5467205 0.82 CFTR (0.56) CFTRANO1CNR2CNR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885ANO1 3245/4885CNR2 2272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.